Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — Announcement | 17 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company completes acquisition of 85% stake in Aequitas Healthcare.

Jagsonpal Pharmaceuticals announced completion of its acquisition of an 85% equity stake in Aequitas Healthcare Private Limited, finalizing a deal previously disclosed on June 29 and updated on July 7 and 8, 2026, marking a strategic expansion into healthcare services.

📄 View Original Announcement (PDF)

About Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹1,574.78 Cr P/E: 35.2 ROE: 19.0% ROCE: 25.8% Div Yield: 1.67%

View full JAGSNPHARM stock details →

📡 Get AI alerts when JAGSNPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JAGSNPHARM — Free

📊 More JAGSNPHARM filings

See all JAGSNPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JAGSNPHARM files new disclosures

Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JAGSNPHARM — Free

Free account · 2 AI queries/day